Bob Steinberg is a partner in both the Los Angeles and Washington D.C. offices of Latham & Watkins. His practice in Washington, D.C. is exclusively before the US Patent and Trademark Office (USPTO) and courts of the United States consistent with D.C Court of Appeals Rule 49(c)(2) and (3). Mr. Steinberg is a member of the firm’s Litigation & Trial Department as well as Chair of Latham’s Patent Trial and Appeal Board (PTAB) Practice and former global Co-chair of the Intellectual Property Practice. The group’s strategic development and unique trial and PTAB capabilities were featured in an article in The Recorder, anALM publication.
Mr. Steinberg is a founding member of the national PTAB Bar Association and was elected as the first President to the Association (www.PTABBar.org). He is also a registered patent attorney and has served in most of the firm’s PTAB proceedings for clients such as AbbVie Biotechnology Ltd., Actifio, NVIDIA and Qualtrics.
He has been instrumental in establishing Latham’s PTAB practice group. The group pioneered innovative approaches to the bourgeoning area of PTAB proceedings, and has maintained an outstanding success rate in persuading the PTAB to institute our client’s petitions and a more than 96% success rate with final determinations. IAM Patent 1000recognized Mr. Steinberg and noted that he “has had a full schedule of late, given his chairmanship of the post-grant practice; he is supremely on top of things, though, as his high inter partes review institution rate attests.” Mr. Steinberg was part of Latham’s team to successfully obtain final written decision in the PTAB on behalf of Actifio against Delphix, with a sweeping victory, invalidating 109 of 111 challenged claims across five patents; Jaguar Land Rover to defeat Cruise Control Technologies (a shell company of patent troll Empire IP); and Qualtrics to invalidate four of OpinionLab, Inc. patents. Mr. Steinberg also worked with the team that obtained a denial of institution on behalf of AbbVie in Amgen’s IPR petitions filed against AbbVie’s patent covering the blockbuster biosimilar drug Humira.
Mr. Steinberg has continuously been recognized as a leading lawyer byThe Legal 500 US and Chambers USA. He was named among the 2012 Who’s Who for Intellectual Property Law by Los Angeles Business Journal and among the top IP litigators in California by The Daily Journal in 2011. Mr. Steinberg was particularly cited for his representation of the Ansel Adams Publishing Rights Trust in a dispute with a defendant who claimed to possess long-lost negatives created by the famous nature photographer – which the Trust maintained were not authentic. He also assisted AMD to secure a US$1.25 billion worldwide settlement in a patent, contract and antitrust dispute with Intel.
Mr. Steinberg also served on the 2014 Law360 Intellectual Property Editorial Advisory Board.
Prior to joining Latham, Mr. Steinberg worked as the Chairman and CEO of xSides Corporation, a developer of desktop security software. He also spent 11 years at Irell & Manella where he was partner and member of the Executive Committee.